Skip to content

Invitris

YC W23 · Active · Creating new protein-based drugs at scale

Competitors

Adjacent

Also from W23

All of W23

About Invitris

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

YC batch
W23 · Winter 2023
Status, per YC
Active
Category
Other
Team size
6
Location
Munich, BY, Germany
Checked
1h ago

YC tags: Biotech, Nanotechnology, Drug discovery

Invitris in W23: 274 companies, 68% AI

Invitris: questions

Which YC batch was Invitris in?

Invitris was in Y Combinator's Winter 2023 batch (W23).

Is Invitris still active?

Y Combinator lists Invitris as active.

Where is Invitris based?

Invitris lists Munich, BY, Germany as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.